Tim F. Greten

53.5k total citations · 16 hit papers
292 papers, 21.7k citations indexed

About

Tim F. Greten is a scholar working on Oncology, Immunology and Hepatology. According to data from OpenAlex, Tim F. Greten has authored 292 papers receiving a total of 21.7k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 109 papers in Immunology and 79 papers in Hepatology. Recurrent topics in Tim F. Greten's work include Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (66 papers) and Immunotherapy and Immune Responses (55 papers). Tim F. Greten is often cited by papers focused on Cancer Immunotherapy and Biomarkers (66 papers), Hepatocellular Carcinoma Treatment and Prognosis (66 papers) and Immunotherapy and Immune Responses (55 papers). Tim F. Greten collaborates with scholars based in United States, Germany and France. Tim F. Greten's co-authors include Firouzeh Korangy, Michael P. Manns, Austin G. Duffy, Lars A. Ormandy, Florian R. Greten, Bernd Heinrich, Martin F. Kagnoff, Zhiwei Li, Lars Eckmann and Jin Mo Park and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Tim F. Greten

284 papers receiving 21.5k citations

Hit Papers

IKKβ Links Inflammation a... 2004 2026 2011 2018 2004 2016 2012 2008 2021 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
    2004 2.0k citations Florian R. Greten, Tim F. Greten et al. profile →
  2. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
    2016 2.0k citations Vincenzo Bronte, Sven Brandau et al. Nature Communications profile →
  3. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer
    2012 1.2k citations Josep M. Llovet, Tim F. Greten et al. profile →
  4. A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
    2008 653 citations Bastian Hoechst, Michael P. Manns et al. profile →
  5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
    2021 633 citations Josep M. Llovet, Tim F. Greten et al. profile →
  6. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
    2016 569 citations Chi Ma, Tobias Eggert et al. profile →
  7. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor #
    2009 529 citations Bastian Hoechst, Jaba Gamrekelashvili et al. Hepatology profile →
  8. Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma
    2005 527 citations Michael P. Manns, Tim F. Greten et al. Cancer Research profile →
  9. Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
    2019 513 citations Lichun Ma, Jonathan M. Hernandez et al. profile →
  10. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression
    2016 447 citations Tobias Eggert, Chi Ma et al. profile →
  11. Gut microbiome in HCC – Mechanisms, diagnosis and therapy
    2020 259 citations Tim F. Greten et al. Journal of Hepatology profile →
  12. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
    2020 240 citations Josep M. Llovet, Tim F. Greten et al. Hepatology profile →
  13. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
    2023 203 citations Josep M. Llovet, Tim F. Greten et al. profile →
  14. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma
    2021 189 citations Lichun Ma, Ching-Wen Chang et al. Journal of Hepatology profile →
  15. Biomarkers for immunotherapy of hepatocellular carcinoma
    2023 109 citations Tim F. Greten, Firouzeh Korangy et al. profile →
  16. Immunology and immunotherapy of cholangiocarcinoma
    2023 102 citations Tim F. Greten, Lichun Ma et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim F. Greten United States 70 9.6k 8.4k 5.5k 4.8k 3.8k 292 21.7k
Eli Pikarsky Israel 54 3.6k 0.4× 5.0k 0.6× 8.8k 1.6× 3.5k 0.7× 2.8k 0.7× 135 18.1k
Gennaro Ciliberto Italy 73 5.9k 0.6× 7.2k 0.9× 9.5k 1.7× 1.7k 0.4× 2.9k 0.8× 435 22.3k
Jesús Prìeto Spain 82 5.0k 0.5× 6.0k 0.7× 8.7k 1.6× 7.9k 1.7× 6.8k 1.8× 606 24.6k
M. Kay Washington United States 78 2.6k 0.3× 6.5k 0.8× 8.4k 1.5× 1.9k 0.4× 2.8k 0.7× 360 21.1k
Bruno Sangro Spain 77 3.2k 0.3× 7.6k 0.9× 4.2k 0.8× 16.2k 3.4× 8.4k 2.2× 416 26.0k
Irene Oi‐Lin Ng Hong Kong 97 3.1k 0.3× 7.9k 0.9× 15.4k 2.8× 9.3k 1.9× 5.7k 1.5× 483 31.4k
Tetsuo Takehara Japan 61 3.5k 0.4× 2.2k 0.3× 3.9k 0.7× 4.4k 0.9× 5.3k 1.4× 482 13.6k
Geoffrey W. McCaughan Australia 73 3.4k 0.4× 4.7k 0.6× 3.1k 0.6× 8.7k 1.8× 8.4k 2.2× 528 20.3k
Jessica Zucman‐Rossi France 82 2.5k 0.3× 7.2k 0.9× 13.9k 2.5× 9.0k 1.9× 6.4k 1.7× 322 31.8k
Anthony J. Demetris United States 81 3.7k 0.4× 3.0k 0.4× 3.4k 0.6× 8.4k 1.8× 5.3k 1.4× 379 23.3k

Countries citing papers authored by Tim F. Greten

Since Specialization
Citations

This map shows the geographic impact of Tim F. Greten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim F. Greten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim F. Greten more than expected).

Fields of papers citing papers by Tim F. Greten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim F. Greten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim F. Greten. The network helps show where Tim F. Greten may publish in the future.

Co-authorship network of co-authors of Tim F. Greten

This figure shows the co-authorship network connecting the top 25 collaborators of Tim F. Greten. A scholar is included among the top collaborators of Tim F. Greten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim F. Greten. Tim F. Greten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Greten, Tim F., et al.. (2025). Disparities in Cholangiocarcinoma Research and Trials: Challenges and Opportunities in the United States. JCO Global Oncology. 11(11). e2400537–e2400537. 1 indexed citations
3.
Huang, Patrick, Xin Wang, Noémi Kedei, et al.. (2025). SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases. Nature Communications. 16(1). 4242–4242. 12 indexed citations
4.
Huang, Patrick, et al.. (2025). Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer. JHEP Reports. 7(5). 101380–101380. 1 indexed citations
5.
Fu, Yaojie, et al.. (2024). Alcohol-associated liver cancer. Hepatology. 80(6). 1462–1479. 17 indexed citations
6.
Monge, Cecilia, Changqing Xie, Yuta Myojin, et al.. (2023). Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. Journal for ImmunoTherapy of Cancer. 11(2). e005640–e005640. 46 indexed citations
7.
McVey, John C., Benjamin L. Green, Benjamin Ruf, et al.. (2022). NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. iScience. 25(2). 103847–103847. 18 indexed citations
8.
Atkins, Michael B., Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.. (2022). Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for ImmunoTherapy of Cancer. 10(9). e005413–e005413. 7 indexed citations
9.
Hung, Man‐Hsin, Joo Sang Lee, Chi Ma, et al.. (2021). Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nature Communications. 12(1). 1455–1455. 163 indexed citations
10.
Xie, Changqing, Austin G. Duffy, Gagandeep Brar, et al.. (2020). Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 26(10). 2318–2326. 65 indexed citations
11.
Khanna, Swati, Francis Mussai, Anish Thomas, et al.. (2018). Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. Clinical Cancer Research. 24(12). 2859–2872. 43 indexed citations
12.
Duffy, Austin G., Chi Ma, Susanna V. Ulahannan, et al.. (2017). Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research. 23(16). 4633–4641. 68 indexed citations
13.
Greten, Tim F.. (2017). Immunotherapy of hepatocellular carcinoma. ˜The œbiomedical & life sciences collection.. 2017(7). e1004455–e1004455. 1 indexed citations
14.
Bronte, Vincenzo, Sven Brandau, Shu‐Hsia Chen, et al.. (2016). Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications. 7(1). 12150–12150. 2010 indexed citations breakdown →
15.
Medina‐Echeverz, José, Chi Ma, Austin G. Duffy, et al.. (2015). Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research. 3(5). 557–566. 40 indexed citations
16.
Raoul, Jean‐Luc, Jordi Bruix, Tim F. Greten, et al.. (2012). Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology. 56(5). 1080–1088. 102 indexed citations
17.
Hoechst, Bastian, Jaba Gamrekelashvili, Michael P. Manns, Tim F. Greten, & Firouzeh Korangy. (2011). Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood. 117(24). 6532–6541. 198 indexed citations
18.
Krüger, Christa, Tim F. Greten, & Firouzeh Korangy. (2007). Immune based therapies in cancer.. PubMed. 22(6). 687–96. 21 indexed citations
19.
Garbe, Annette I., Jaba Gamrekelashvili, Reinhard von Wasielewski, et al.. (2006). Genetically Induced Pancreatic Adenocarcinoma Is Highly Immunogenic and Causes Spontaneous Tumor-Specific Immune Responses. Cancer Research. 66(1). 508–516. 34 indexed citations
20.
Sinha, Bhanu, et al.. (1998). Nitric oxide downregulates tumour necrosis factor mRNA in RAW 264.7 cells. Research in Immunology. 149(2). 139–150. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eli Pikarsky Breakdown of academic impact, for papers by Gennaro Ciliberto Breakdown of academic impact, for papers by Jesús Prìeto Breakdown of academic impact, for papers by M. Kay Washington Breakdown of academic impact, for papers by Bruno Sangro Breakdown of academic impact, for papers by Irene Oi‐Lin Ng Breakdown of academic impact, for papers by Tetsuo Takehara Breakdown of academic impact, for papers by Geoffrey W. McCaughan Breakdown of academic impact, for papers by Jessica Zucman‐Rossi Breakdown of academic impact, for papers by Anthony J. Demetris
Rankless by CCL
2026